Eton Pharmaceuticals (ETON) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 09, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-38738
Entity Registrant Name	ETON PHARMACEUTICALS, INC.
Entity Central Index Key	0001710340
Entity Tax Identification Number	37-1858472
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	21925 W. Field Parkway
Entity Address, Address Line Two	Suite 235
Entity Address, City or Town	Deer Park
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60010-7278
City Area Code	(847)
Local Phone Number	787-7361
Title of 12(b) Security	Common stock, $0.001 par value per share
Trading Symbol	ETON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		24,600,175

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 25,802	$ 21,295
Accounts receivable, net	303	48
Inventories	1,242	1,242
Prepaid expenses and other current assets	1,728	2,116
Total current assets	29,075	24,701
Property and equipment, net	156	811
Intangible assets, net	500	575
Operating lease right-of-use assets, net	143	192
Other long-term assets, net	32	40
Total assets	29,906	26,319
Current liabilities:
Accounts payable	1,522	2,344
Current portion of long-term debt	749
PPP loan, current portion		280
Accrued liabilities	835	1,170
Total current liabilities	3,106	3,794
Long-term debt, net of discount and including accrued fees	5,856	6,532
Long-term portion of PPP and EIDL loans	150	231
Operating lease liabilities, net of current portion	58	99
Total liabilities	9,170	10,656
Commitments and contingencies (Note 12)
Stockholders’ equity
Common stock, $0.001 par value; 50,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 24,600,175 and 24,312,808 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	25	24
Additional paid-in capital	109,769	107,797
Accumulated deficit	(89,058)	(92,158)
Total stockholders’ equity	20,736	15,663
Total liabilities and stockholders’ equity	$ 29,906	$ 26,319

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	24,600,175	24,312,808
Common stock, shares outstanding	24,600,175	24,312,808

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues:
Total net revenues	$ 3,067	$ 20	$ 14,964	$ 119
Cost of sales:
Total cost of sales	136	28	1,726	130
Gross profit (loss)	2,931	(8)	13,238	(11)
Operating expenses:
Research and development	1,990	1,609	2,876	7,877
General and administrative	3,266	2,921	7,324	5,531
Total operating expenses	5,256	4,530	10,200	13,408
(Loss) income from operations	(2,325)	(4,538)	3,038	(13,419)
Other (expense) income:
Interest and other (expense) income, net	(237)	(192)	(484)	(360)
Gain on PPP loan forgiven	365		365
Gain on equipment sale	181		181
(Loss) income before income tax expense	(2,016)	(4,730)	3,100	(13,779)
Income tax expense
Net (loss) income	$ (2,016)	$ (4,730)	$ 3,100	$ (13,779)
Net loss (income) per share, basic	$ (0.08)	$ (0.23)	$ 0.12	$ (0.70)
Net loss (income) per share, diluted	$ (0.08)	$ (0.23)	$ 0.12	$ (0.70)
Weighted average number of common shares outstanding, basic	25,211,277	21,004,910	25,132,776	19,574,164
Weighted average number of common shares outstanding, diluted	25,211,277	21,004,910	26,485,655	19,574,164
Licensing Revenue [Member]
Revenues:
Total net revenues	$ 2,500		$ 14,000
Cost of sales:
Total cost of sales			1,500
Product [Member]
Revenues:
Total net revenues	567	20	964	119
Cost of sales:
Total cost of sales	$ 136	$ 28	$ 226	$ 130

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance at Dec. 31, 2019	$ 18	$ 74,720	$ (64,188)	$ 10,550
Beginning balance, shares at Dec. 31, 2019	17,877,486
Stock-based compensation		1,079		1,079
Stock-based compensation, shares	15,190
Stock option exercises		97		97
Stock option exercises, shares	69,878
Employee stock purchase plan		64		64
Employee stock purchase plan, shares	14,005
Proceeds from sales of common stock, net of offering costs	$ 3	7,753		7,756
Proceeds from sales of common stock, net of offering costs, shares	2,600,000
Issuance of common stock for product candidate licensing rights		1,264		1,264
Issuance of common stock for product candidate licensing rights, shares	379,474
Net loss			(13,779)	(13,779)
Ending balance at Jun. 30, 2020	$ 21	84,977	(77,967)	7,031
Ending balance, shares at Jun. 30, 2020	20,956,033
Beginning balance at Mar. 31, 2020	$ 21	83,836	(73,237)	10,620
Beginning balance, shares at Mar. 31, 2020	20,761,960
Stock-based compensation		714		714
Stock-based compensation, shares	15,190
Stock option exercises		66		66
Stock option exercises, shares	64,878
Employee stock purchase plan		64		64
Employee stock purchase plan, shares	14,005
Proceeds from sales of common stock, net of offering costs		297		297
Proceeds from sales of common stock, net of offering costs, shares	100,000
Net loss			(4,730)	(4,730)
Ending balance at Jun. 30, 2020	$ 21	84,977	(77,967)	7,031
Ending balance, shares at Jun. 30, 2020	20,956,033
Beginning balance at Dec. 31, 2020	$ 24	107,797	(92,158)	15,663
Beginning balance, shares at Dec. 31, 2020	24,312,808
Stock-based compensation		1,509		1,509
Stock-based compensation, shares
Stock option exercises	$ 1	329		330
Stock option exercises, shares	138,233
Employee stock purchase plan		134		134
Employee stock purchase plan, shares	29,326
Common stock issued related to restricted stock units
Stock Issued During Period, Shares, Restricted Stock Award, Gross	25,000
Warrant exercises
Warrant exercises, shares	94,808
Net loss			3,100	3,100
Ending balance at Jun. 30, 2021	$ 25	109,769	(89,058)	20,736
Ending balance, shares at Jun. 30, 2021	24,600,175
Beginning balance at Mar. 31, 2021	$ 24	108,573	(87,042)	21,555
Beginning balance, shares at Mar. 31, 2021	24,482,616
Stock-based compensation		836		836
Stock-based compensation, shares
Stock option exercises		226		226
Stock option exercises, shares	63,233
Employee stock purchase plan		134		134
Employee stock purchase plan, shares	29,326
Common stock issued related to restricted stock units
Stock Issued During Period, Shares, Restricted Stock Award, Gross	25,000
Net loss			(2,016)	(2,016)
Ending balance at Jun. 30, 2021	$ 25	$ 109,769	$ (89,058)	$ 20,736
Ending balance, shares at Jun. 30, 2021	24,600,175

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net income (loss)	$ 3,100	$ (13,779)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation	1,509	1,079
Common stock issued for product candidate licensing rights		1,264
Depreciation and amortization	240	326
Debt discount amortization	73	50
Gain on forgiveness of debt	(365)
Gain on sale of equipment	(181)
Changes in operating assets and liabilities:
Accounts receivable	(255)	473
Inventories		(1,329)
Prepaid expenses and other assets	419	1,251
Accounts payable	(822)	1,378
Accrued liabilities	(372)	(783)
Net cash used in operating activities	3,346	(10,070)
Cash provided by (used in) investing activities
Proceeds from sale of equipment	700
Purchases of property and equipment	(3)	(4)
Net cash provided by (used in) financing activities	697	(4)
Cash flows from financing activities
Proceeds from sales of common stock, net of offering costs		7,756
Proceeds from PPP loan		361
Proceeds from employee stock purchase plan and stock option exercises	464	161
Net cash provided by financing activities	464	8,278
Change in cash and cash equivalents	4,507	(1,796)
Cash and cash equivalents at beginning of period	21,295	12,066
Cash and cash equivalents at end of period	25,802	10,270
Supplemental disclosures of cash flow information
Cash paid for interest	424	358
Cash paid for income taxes

Company Overview

Company Overview	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Company Overview	Note 1 — Company Overview Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) was incorporated as a Delaware “C” corporation on April 27, 2017 and was initially set up as a wholly-owned subsidiary of Harrow Health, Inc. (“Harrow”, fka Imprimis Pharmaceuticals, Inc.). In June 2017, the Company raised $ 20,055 21,960 4,750 1,965 7,756 21,026 7.00 Eton is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company seeks to improve the formula, delivery system, or safety of existing molecules in order to address unmet patient needs. Eton pursues what it perceives to be low-risk product candidates where existing published literature, historical clinical trials, or physician usage has established safety and/or efficacy of the molecule, thereby reducing the incremental clinical burden required for the Company to bring the product to patients. The Company’s Biorphen® product was approved by the FDA in October 2019 and sales commenced for this product at the end of 2019. Eton’s EM-100 product was sold to Bausch Health and the product was approved by the FDA in September 2020. Bausch Health launched this product under the name of Alaway® Preservative Free in January 2021 and Eton will receive royalties from the sale of the product. In addition, the Company acquired the licensing rights to Alkindi Sprinkle and this product was approved by the FDA in October 2020 and launched in December 2020. In February 2021, the Company sold three pediatric neurology products it had under development to Azurity Pharmaceuticals (“Azurity”) and anticipates additional revenues from Azurity based on various product-related milestones including the commercial launch for these products which are currently under review with the FDA.

Liquidity Considerations

Liquidity Considerations	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity Considerations	Note 2 — Liquidity Considerations In the first six months of 2021, the Company generated net cash provided by operating activities of $ 3,346 Prior to 2021, the Company had generated limited revenues and had incurred negative cash flows from operating activities since its inception in 2017. The Company currently believes its existing cash and cash equivalents of $ 25,802

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 — Summary of Significant Accounting Policies Basis of Presentation The Company has prepared the accompanying financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued) Unaudited Interim Financial Information The accompanying interim condensed financial statements are unaudited and have been prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments necessary for the fair presentation of the Company’s financial position as of June 30, 2021 and the results of its operations and its cash flows for the periods ended June 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and six-month periods ended June 30, 2021 and 2020 are also unaudited. The results for the six-month period ended June 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods or any future year or period. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, provisions for uncollectible receivables and sales returns, valuation of inventories, useful lives of assets and the impairment of property and equipment, the accrual of research and development expenses and the valuation of common stock, stock options and warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions. Segment Information The Company operates the business on the basis of a single Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in U.S. financial institutions or invested in short-term U.S. treasury bills. Cash equivalents consist of an interest-bearing checking account and a U.S. treasury bill. From time to time, amounts deposited with its bank exceed federally insured limits. The Company believes the associated credit risk to be minimal. Accounts Receivable Accounts receivable are recorded at the invoiced amount and are non-interest bearing. Accounts receivable are recorded net of allowances for doubtful accounts, cash discounts for prompt payment, distribution fees, chargebacks and returns and allowances. The total for these reserves amounted to $ 85 71 Inventories The Company values its inventories at the lower of cost or net realizable value using the first-in, first-out method of valuation. The Company reviews its inventories for potential excess or obsolete issues on an ongoing basis and will record a write-down if an impairment is identified. Inventories at June 30, 2021 and December 31, 2020 consist solely of purchased finished goods. At both June 30, 2021 and December 31, 2020 inventories are shown net of a slow-moving reserve for its Biorphen product of $ 623 Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued) Property and Equipment Property and equipment are stated at cost. Depreciation of property and equipment is computed utilizing the straight-line method based on the following estimated useful lives: computer hardware and software is depreciated over three years five years estimated useful lives or the remaining lease term Maintenance and repairs are charged to expense as incurred, while renewals and improvements are capitalized. In March 2021, the Company completed an evaluation of its expected needs for product development and testing activities and determined that it would discontinue its laboratory operation in Lake Zurich, Illinois. The Company completed a sale of the lab equipment in May 2021 at a price of $ 700 which was $ 181 in excess of the book value for these assets. Accordingly, the $ 519 net book value of these assets was removed from the property and equipment accounts and the $ 181 gain is reflected in the Company’s statements of operations for the three and six-month periods ended June 30, 2021. In conjunction with the closing of its laboratory operation, the Company scrapped various furniture and equipment which had a net book value of $ 31 which has been included in research and development expense in the statements of operations. Intangible Assets The Company capitalizes payments it makes for licensed products when the payment is based on FDA approval for the product and the cost is recoverable based on expected future cash flows from the product. The cost is amortized on a straight-line basis over the estimated useful life of the product commencing on the approval date in accordance with Accounting Standards Codification (“ASC”) 350 — Intangibles - Goodwill and Other. A $ 750 payment related to the approval of the Company’s Biorphen product in 2019 has been capitalized and that cost is being amortized over five years. The intangible assets, net on the Company’s balance sheet reflected $ 250 of accumulated amortization as of June 30, 2021. The Company recorded $ 37 75 of amortization expense for the three and six months ended June 30, 2021, respectively. The Company will record amortization expense of $ 150 per year for this intangible asset for 2021 through 2023 and then $ 125 in 2024 when it will be fully amortized. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the Company’s statements of operations for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No Debt Issuance Costs and Debt Discount and Detachable Debt-Related Warrants Costs incurred to issue debt are deferred and recorded as a reduction to the debt balance in the accompanying balance sheets. The Company amortizes debt issuance costs over the expected term of the related debt using the effective interest method. Debt discounts relate to the relative fair value of warrants issued in conjunction with the debt and are also recorded as a reduction to the debt balance and accreted over the expected term of the debt to interest expense using the effective interest method. Revenue Recognition for Contracts with Customers The Company accounts for contracts with its customers in accordance with ASC 606 — Revenue from Contracts with Customers. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued) At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses whether these options provide a material right to the customer and, if so, they are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Any amounts received prior to revenue recognition will be recorded as deferred revenue. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date will be classified as current portion of deferred revenue in the Company’s balance sheets. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as long-term deferred revenue, net of current portion. Milestone Payments Royalties – Significant Financing Component – The Company sells Biorphen in the U.S. to wholesale pharmaceutical distributors, who then sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual shipments of Biorphen represent performance obligations under each purchase order. The Company uses a third-party logistics (“3PL”) vendor to process and fulfill orders and has concluded it is the principal in the sales to wholesalers because it controls access to the 3PL vendor services rendered and directs the 3PL vendor activities. The Company has no significant obligations to wholesalers to generate pull-through sales. In addition, the Company sells its Alkindi Sprinkle product to one pharmacy distributor customer which provides order fulfilment and inventory storage/distribution services. Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when the wholesalers sell Biorphen at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. In addition, the Company pays fees to wholesalers for their distribution services, inventory reporting and chargeback processing. The Company pays GPOs fees for administrative services and for access to GPO members and concluded the benefits received in exchange for these fees are not distinct from its sales of Biorphen, and accordingly it applies these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Biorphen and the Company’s lengthy return period, there may be a significant period of time between when the product is shipped and when it issues credits on returned product. For its Alkindi Sprinkle product, the Company bills at the initial product list price which are subject to offsets for patient co-pay assistance and potential state Medicaid reimbursements which are recorded as a reduction of net revenues at the date of sale/shipment. Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued) The Company estimates the transaction price when it receives each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler/distributor arising from all of the above factors. The Company has developed estimates for future returns and chargebacks of Biorphen and the impact of the other discounts and fees it pays while Alkindi Sprinkle sales to its distributor are not subject to returns. When estimating these adjustments to the transaction price, the Company reduces it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known. The Company recognizes revenue from Biorphen product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay the Company. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, the Company does not believe they have a significant incentive to return the product. The Company stores its Alkindi Sprinkle inventory at its pharmacy distributor customer location and sales are recorded when stock is pulled and shipped to fulfill specific patient orders. Upon recognition of revenue from product sales, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, state Medicaid and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. The Company monitors actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts end up differing from its estimates, it will make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment. In addition, the Company receives revenues from product licensing agreements where it has contracted for milestone payments and royalties from products it has developed or for which it has acquired the rights to a product developed by a third party. Revenues for the three months ended June 30, 2021 reflected $ 2,500 of licensing milestone fees, $ 493 in product sales and $ 74 in royalty revenue. Revenues for the six months ended June 30, 2021 reflected $ 14,000 of licensing milestone fees, $ 747 in product sales and $ 217 in royalty revenue. Revenues for the three and six months ended June 30, 2020 consisted solely of product sales. Cost of Sales Cost of sales consists of the profit-sharing and royalty fees with the Company’s product licensing and development partners, the purchase costs for finished products from third-party manufacturers and freight and handling/storage costs from the Company’s 3PL logistics service providers. The cost of sales for profit-sharing and royalty fees and costs for purchased finished products and the associated inbound freight expense is recorded when the associated product sale revenue is recognized in accordance with the terms of shipment to customers while outbound freight and handling/storage fees charged by the 3PL service provider are expensed as they are incurred. Cost of sales also reflects any write-downs or reserve adjustments for the Company’s inventories. Research and Development Expenses Research and development (“R&D”) expenses include both internal R&D activities and external contracted services. Internal R&D activity expenses include salaries, benefits and stock-based compensation and other costs to support the Company’s R&D operations. External contracted services include product development efforts such as certain product licensor milestone payments, clinical trial activities, manufacturing and control-related activities and regulatory costs. R&D expenses are charged to operations as incurred. The Company reviews and accrues R&D expenses based on services performed and relies upon estimates of those costs applicable to the stage of completion of each project. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. Upfront payments and milestone payments made for the licensing of technology for products that are not yet approved by the FDA are expensed as R&D in the period in which they are incurred. Nonrefundable advance payments for goods or services to be received in the future for use in R&D activities are recorded as prepaid expenses and are expensed as the related goods are delivered or the services are performed. Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued) Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as unvested restricted stock, stock options and warrants that are outstanding during the period. Common stock equivalents are excluded from the computation when their inclusion would be anti-dilutive. Common stock equivalents (using the treasury stock and “if converted” method) from stock options, unvested RSAs and warrants at June 30, 2021 were 1,352,879 and excluded 1,624,598 shares that were anti-dilutive (see Note 9). Included in the basic and diluted net income (loss) per share calculation are RSUs awarded to directors that have vested, but the issuance and delivery of the common shares are deferred until the director retires from service as a director (see Note 8). Basic weighted average shares for the three and six months ended June 30, 2021 include 600,000 0.01 Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of ASC 718 — Compensation — Stock Compensation. The guidance under ASC 718 requires companies to estimate the fair value of the stock-based compensation awards on the date of grant and record expense over the related service periods, which are generally the vesting period of the equity awards. The Company estimates the fair value of stock-based option awards using the Black-Scholes-Merton option-pricing model (“BSM”). The BSM requires the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate was determined from the implied yields for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options or warrants. Dividends on common stock are assumed to be zero for the BSM valuation of the stock options. The expected term of stock options granted is based on vesting periods and the contractual life of the options. Expected volatilities are based on comparable companies’ historical volatility along with a limited weighting included for the Company’s own volatility subsequent to its IPO, which management believes represents the most accurate basis for estimating expected future volatility under the current conditions. The Company accounts for forfeitures as they occur. Fair Value Measurements We measure certain of our assets and liabilities at fair value. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value accounting requires characterization of the inputs used to measure fair value into a three-level fair value hierarchy as follows: Level 1 Level 2 Level 3 Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below take into account the market for the Company’s financials, assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued) The Company’s financial instruments included cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, PPP loan and long-term debt obligation. The carrying amounts of these financial instruments, except for the PPP loan and long-term debt obligation, approximate their fair values due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying value of the PPP loan and long-term debt obligation approximate their fair values. Impact of New Accounting Pronouncements There were no new accounting pronouncements issued by the FASB during the current period that would apply to the Company and have a material impact on its financial position or results of operations. Subsequent Events The Company has evaluated subsequent events through the filing date of this Form 10-Q and has determined that no subsequent events have occurred that would require recognition in the condensed financial statements or disclosure in the notes thereto, except as disclosed in the notes to these condensed financial statements.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4 — Property and Equipment Property and equipment consist of the following: Schedule of Property and Equipment June 30, December 31, Computer hardware and software $ 153 $ 182 Furniture and fixtures 105 143 Equipment 132 994 Leasehold improvements 71 184 Property and equipment, gross 461 1,503 Less: accumulated depreciation (305 ) (692 ) Property and equipment, net $ 156 $ 811 Depreciation expense for the three-month periods ended June 30, 2021 and 2020 was $ 24 and $ 87 , respectively. Depreciation expense for the six-month periods ended June 30, 2021 and 2020 was $ 108 and $ 174 , respectively. The balances at June 30, 2021 reflect the sale of laboratory equipment in May 2021 which had a net book value of $ 519 . In conjunction with the closing of its laboratory operation, the Company scrapped various furniture and equipment which had a net book value of $ 31, which is included in research and development expense in the statements of operations.

Long-Term Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Long-Term Debt	Note 5 — Long-Term Debt SWK Loan On November 13, 2019, the Company entered into a credit agreement (the “SWK Credit Agreement”) with SWK Holdings Corporation (“SWK”) which provided for up to $ 10,000 5,000 5,000 2,000 2,000 10.0% 2.0% 2.0% 5.0% 3,000 Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 5 — Long Term Debt (continued) The SWK Credit Agreement contains customary default provisions and covenants which include limits on additional indebtedness. In March 2020, SWK provided a waiver for the Company to obtain loans with the Small Business Association. The Company is currently in the process of negotiating covenant targets for EBITDA and revenue for the SWK Credit Agreement. In February 2021, the Company notified SWK that it will not require additional borrowing capacity under the SWK Credit Agreement and terminated the additional borrowing capacity with SWK. In connection with the initial $ 5,000 borrowed in November 2019, the Company issued warrants to SWK to purchase 51,239 shares of the Company’s common stock with an exercise price of $ 5.86 per share. The relative fair value of the 51,239 warrants was $ 226 and was estimated using the Black-Scholes-Merton option pricing model with the following assumptions: fair value of the Company’s common stock at issuance of $ 5.75 per share; seven-year contractual term; 95 % volatility; 0 % dividend rate; and a risk-free interest rate of 1.8 %. In connection with the additional $ 2,000 18,141 6.62 94 6.85 seven-year 95 0 0.4 These warrants (the “SWK Warrants”) are exercisable immediately and have a term of seven years from the date of issuance. The SWK Warrants contain a cashless exercise feature, with the exercise price and number of shares issuable upon exercise subject to change in connection with stock splits, dividends, reclassifications and other conditions. Interest expense of $ 513 73 386 50 64 The table below reflects the future payments for the SWK loan principal and interest as of June 30, 2021. Schedule of Future Payments of Long Term Debt Amount 2021 $ 384 2022 2,202 2023 1,756 2024 5,300 Total payments 9,642 Less: amount representing interest (2,642 ) Loan payable, gross 7,000 Less: current portion of long-term debt (749 ) Less: unamortized discount (395 ) Long-term debt, net of unamortized discount $ 5,856 PPP loan On May 4, 2020, the Company received $ 361 4 365 EIDL loan On July 21, 2020, the Company received $ 150 6 Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited)

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Common Stock	Note 6 — Common Stock The Company has 50,000,000 0.001 During the six months ended June 30, 2021, the Company issued 138,233 shares of its common stock resulting from stock option exercises under its 2018 Equity Incentive Plan (see Note 8). In April 2021, the Company issued 25,000 shares of common stock to a member of its board of directors upon his retirement from the board in connection with previously vested restricted stock units (“RSUs”). During the six months ended June 30, 2021, a holder of the Company’s common stock warrants exercised 135,650 94,808 806 In June 2021, the Company issued 29,326

Common Stock Warrants

Common Stock Warrants	6 Months Ended
	Jun. 30, 2021
Common Stock Warrants
Common Stock Warrants	Note 7 — Common Stock Warrants The Company’s outstanding warrants to purchase shares of its common stock at June 30, 2021 are summarized in the table below. Summary of Warrants Outstanding Description of Warrants No. of Shares Exercise Price Business Advisory Warrants 600,000 $ 0.01 Placement Agent Warrants – 2017 Preferred Stock Offering 471,446 $ 3.00 Placement Agent Warrants - IPO 414,000 $ 7.50 SWK Warrants – Debt – Tranche #1 51,239 $ 5.86 SWK Warrants – Debt – Tranche #2 18,141 $ 6.62 Total 1,554,826 $ 3.18 ) The holders of these warrants or their permitted transferees, are entitled to rights with respect to the registration under the Securities Act of 1933, as amended (the “Securities Act”) for their shares that are converted to common stock, including demand registration rights and piggyback registration rights. These rights are provided under the terms of a registration rights agreement between the Company and the investors. Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited)

Share-Based Payment Awards

Share-Based Payment Awards	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Share-Based Payment Awards	Note 8 — Share-Based Payment Awards The Company’s board of directors and stockholders approved the Eton Pharmaceuticals, Inc. 2017 Equity Incentive Plan in May 2017 (the “2017 Plan”), which authorized the issuance of up to 5,000,000 shares of the Company’s common stock. In conjunction with the Company’s IPO in November 2018, the Company’s stockholders and board of directors approved the 2018 Equity Incentive Plan (as amended in January 2021, the “2018 plan”) which succeeded the 2017 Plan. The Company has granted restricted stock awards (“RSAs”), stock options and RSUs for its common stock under the 2017 Plan and 2018 Plan as detailed in the tables below. There were 481,160 shares available for future issuance under the 2018 Plan as of June 30, 2021. Shares that are expired, terminated, surrendered or canceled without having been fully exercised will be available for future awards under the 2018 Plan. In addition, the 2018 Plan provides that commencing January 1, 2019 and through January 1, 2028, the share reserve will be increased annually by 4 During the third quarter of 2017, the Company issued 25,000 100 100,000 25,000 To date, all stock options issued have been non-qualified stock options, and the exercise prices were set at the fair value for the shares at the dates of grant. Options typically have a ten-year 50,000 five-year For the three months ended June 30, 2021 and 2020, the Company’s total stock-based compensation expense was $ 836 and $ 714 , respectively. Of these amounts, $ 691 and $ 651 was recorded in general and administrative expenses, respectively, and $ 145 and $ 63 was recorded in research and development expenses, respectively. For the six months ended June 30, 2021 and 2020, the Company’s total stock-based compensation expense was $ 1,509 1,079 1,272 976 237 103 Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 8 — Share-Based Payment Awards (continued) A summary of stock option activity is as follows: Summary of Stock Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Yrs) Aggregate Intrinsic Value Options outstanding as of December 31, 2020 2,824,500 $ 4.05 8.3 $ 11,525 Issued 902,098 $ 8.61 Exercised (138,233 ) $ 2.39 Forfeited/Cancelled (12,500 ) $ 7.31 Options outstanding as of June 30, 2021 3,575,865 $ 5.25 8.4 $ 6,335 Options exercisable at June 30, 2021 1,506,614 $ 4.21 7.7 $ 3,556 Options vested and expected to vest at June 30, 2021 3,525,865 $ 5.31 8.4 $ 6,096 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had strike prices lower than the fair value of the Company’s common stock. The assumptions used to calculate the fair value of options granted during the six months ended June 30, 2021 under the BSM were as follows: Schedule of Assumptions Used to Calculate Fair Value of Options Granted Expected dividends — % Expected volatility 80 % Risk-free interest rate 0.9 1.1 % Expected term 5.3 6.3 Weighted average fair value $ 5.88 Expected Term — The Company has opted to use the “simplified method” for estimating the expected term of options granted to employees and directors, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally ten years). The expected term of options granted to non-employees equals the contractual life of the options. Expected Volatility — Due to the Company’s limited operating history and a lack of Company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The Company has continued this methodology plus given some limited weighting to its own volatility in the periods subsequent to its November 2018 IPO. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. Risk-Free Interest Rate — The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the Company’s stock options. Expected Dividend — The Company has not issued any dividends in its history and does not expect to issue dividends over the life of the options and therefore has estimated the dividend yield to be zero Fair Value of Common Stock —The Company uses the closing stock price on the date of grant for the fair value of the common stock. Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 8 — Share-Based Payment Awards (continued) As of June 30, 2021, there was a total of $ 8,242 of unrecognized compensation costs related to non-vested stock option and restricted awards. In the six-month period ended June 30, 2021, there were four stock option exercises which totaled 138,233 shares at an average exercise price of $ 2.39 per share with an intrinsic value of $ 661 . There were four stock option exercises for 69,878 shares during the six months ended June 30, 2020 at an average exercise price of $ 1.39 per share with an intrinsic value of $ 139 . In December 2018, the Company’s board of directors approved and adopted an initial offering of the Company’s common stock under the Company’s 2018 ESPP. The Company’s ESPP provides for an initial reserve of 150,000 500,009 The initial offering of the ESPP began on December 17, 2018 and ended on December 10, 2019. The annual offerings consist of two stock purchase periods, with the first purchase period ending in June and the second purchase period ending in December. The terms of the ESPP permit employees of the Company to use payroll deductions to purchase stock at a price per share that is at least the lesser of (1) 85% of the fair market value of a share of common stock on the first date of an offering or (2) 85% of the fair market value of a share of common stock on the date of purchase. After the initial offering period ended, subsequent twelve-month offering periods automatically commence over the term of the ESPP on the day that immediately follows the conclusion of the preceding offering, each consisting of two purchase periods approximately six months in duration. For the first six months of 2021 and 2020 there were 29,326 14,005 2.83 2.43 135 66 46 33 19 9 Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited)

Earnings (Loss) Per Share

Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	Note 9 — Earnings (Loss) Per Share Basic and diluted net income (loss) per share was calculated as follows: Schedule of Basic and Diluted Net Income (Loss) Per Share 2021 2020 2021 2020 Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Basic net income (loss) per share: Numerator: Net income (loss) $ (2,016 ) $ (4,730 ) $ 3,100 $ (13,779 ) Denominator: Weighted-average number of common shares outstanding, basic 25,211,277 21,004,910 25,132,776 19,574,164 Net income (loss) per share, basic $ (0.08 ) $ (0.23 ) $ 0.12 $ (0.70 ) Diluted net income (loss) per share: Numerator: Net income (loss) $ (2,016 ) $ (4,730 ) $ 3,100 $ (13,779 ) Denominator: Weighted-average number of common shares outstanding, basic 25,211,277 21,004,910 25,132,776 19,574,164 Dilutive effect of stock awards and warrants — — 1,352,879 — Weighted-average number of common shares outstanding, diluted 25,211,277 21,004,910 26,485,655 19,574,164 Net income (loss) per share, diluted $ (0.08 ) $ (0.23 ) $ 0.12 $ (0.70 ) Potential shares of common stock that were excluded from the computation of diluted earnings per common share as their effect was anti-dilutive: Stock awards and warrants 4,266,079 3,307,335 1,624,598 3,972,785 There was no difference between the Company’s net income (loss) and the net income (loss) attributable to common stockholders for all periods presented.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 10 — Related Party Transactions Harrow Harrow was issued 3,500,000 0.001 On May 6, 2019, the Company entered into an Asset Purchase Agreement (the “CT-100 Asset Purchase Agreement”) with Harrow. Pursuant to the CT-100 Asset Purchase Agreement, the Company sold all of its right, title and interest in CT-100 to Harrow, including any such product that incorporates or utilizes its intellectual property rights (a “Product” or, collectively, “Products”). Pursuant to the CT-100 Asset Purchase Agreement, Harrow will make certain payments to the Company upon the achievement of certain development and commercial milestones. In addition, Harrow is required to pay the Company a royalty in the low-single digit percentage range worldwide on a country-by-country basis on net sales for a period of the longer of 15 years from the date of the first commercial sale of a product in a particular country or the time that a valid intellectual property claim on such Product remains in force in the applicable country. The CT-100 Asset Purchase Agreement also contains customary representations, warranties, covenants and indemnities by the parties. As part of the early start-up for the Company’s pharmaceutical business in 2017, key executives at Harrow received a total of 1,500,000 130,000 20,000 Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 10 — Related Party Transactions (continued) Additionally, the Chief Executive Officer of Harrow was a member of the Company’s board of directors until March 17, 2021 when he retired from service with the board. The Company issued 25,000 In late March 2021, the Company closed its laboratory operation in Lake Zurich, Illinois and in May 2021 it reached an agreement for Imprimis Pharmaceuticals, a subsidiary of Harrow, to its our lab equipment for $ 700 which was $ 181 above the Companys’s net book value of the equipment. Chief Executive Officer The CEO has a partial interest in a company that the Company has partnered with for its EM-100 product as described below. The Company acquired the exclusive rights to sell the EM-100 product in the United States pursuant to a sales and marketing agreement (the “Eyemax Agreement”) dated August 11, 2017 between the Company and Eyemax LLC (“Eyemax”), an entity affiliated with the Company’s CEO. The Company also held a right of first refusal to obtain the exclusive license rights for geographic areas outside of the United States. Pursuant to the Eyemax Agreement, the Company was responsible for all costs of testing and FDA approval of the product, other than the FDA filing fee which was paid by Eyemax. The Company was also to be responsible for commercializing the product in the United States at its expense. The Company paid Eyemax $ 250 250 500 10 The Eyemax Agreement was for an initial term of 10 On February 18, 2019, The Company entered into an Amended and Restated Agreement with Eyemax amending the Eyemax Agreement (the “Amended Agreement”). Pursuant to the Amended Agreement, Eyemax sold the Company all of its right, title and interest in EM-100, including any such product that incorporates or utilizes Eyemax’s intellectual property rights. Under the Amended Agreement, the Company assumed certain liabilities of Eyemax under its Exclusive Development & Supply Agreement with Excelvision SAS dated as of July 11, 2013, as amended (the “Excelvision Agreement”), with respect to certain territories and arising during certain time periods. Pursuant to the Amended Agreement, the Company was obligated to pay Eyemax two milestone payments: (i) one milestone payment for $ 250 500 2,000 Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited)

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases
Leases	Note 11 — Leases The Company recognizes a right-of-use (“ROU”) asset and a lease liability on the balance sheet for substantially all leases, including operating leases, and separates lease components from non-lease components related to its office space lease. The Company’s operating lease cost as presented in the “Research and Development” and “General and Administrative” captions in the condensed statements of operations was $ 0 22 14 20 9 43 28 41 43 20 49 33 64 1.75 5.4 The table below presents the lease-related assets and liabilities recorded on the balance sheet as of June 30, 2021 (in thousands). Schedule of Lease-related Assets and Liabilities Assets Classification Operating lease right-of-use assets Operating lease right-of-use assets, net $ 143 Total leased assets $ 143 Liabilities Operating lease liabilities, current Accrued liabilities $ 81 Operating lease liabilities, noncurrent Operating lease liabilities, net of current portion 58 Total operating lease liabilities $ 139 The Company’s future lease commitments for its administrative offices in Deer Park, Illinois as of June 30, 2020 are as indicated below: Schedule of Future Lease Commitments Total 2021 2022 2023 Thereafter Undiscounted lease payments $ 145 43 88 14 — Less: Imputed interest (6 ) Total lease liabilities $ 139 Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited)

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12 — Commitments and Contingencies Legal The Company is subject to legal proceedings and claims that may arise in the ordinary course of business. The Company is not aware of any pending or threatened litigation matters at this time that may have a material impact on the operations of the Company. License and product development agreements The Company has entered into various agreements in addition to those discussed above which are described below. The Company acquired the exclusive rights to sell the Cysteine injection product in the United States pursuant to a sales and marketing agreement dated November 17, 2017 with an unaffiliated third party (the “Sales Agreement”). Pursuant to the Sales Agreement, the licensor is responsible for obtaining FDA approval, at its expense, and the Company is responsible for commercializing the product in the United States at its expense. The Company was to pay the third party 50 62.5 10 On February 8, 2019, the Company entered into an Exclusive Licensing and Supply Agreement (the “ET-202 License Agreement”) with Sintetica SA (“Sintetica”) for marketing rights in the United States to Biorphen® which is used for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. The product was submitted to the FDA for review and subsequently received FDA approval on October 21, 2019. Pursuant to the terms of the ET-202 License Agreement, the Company is responsible for marketing activities and Sintetica is responsible for development, manufacturing, and the regulatory activities related to approval. The Company paid Sintetica a licensing payment of $ 2,000 750 5 500 50 50 ten On February 8, 2019, the Company also entered into an Exclusive Licensing and Supply Agreement (the “ET-203 License Agreement”) with Sintetica for marketing rights in the United States to ephedrine, an injectable product candidate for use in the hospital setting. Pursuant to the terms of the ET-203 License Agreement, the Company will be responsible for marketing activities and Sintetica will be responsible for development, manufacturing, and regulatory activities related to obtaining regulatory approval. The Company paid Sintetica a licensing payment of $ 1,000 600 750 5 500 50 50 ten-year The three oral solution pediatric neurology product candidates discussed below, Topiramate, Zonisamide and Lamotrigine were developed by the Company and its various product candidate development partners and the Company subsequently sold all its rights and interests in these three products to Azurity Pharmaceuticals, Inc. (“Azurity”) in 2021. During the years ended December 31, 2020, 2019 and 2018, the Company worked with Tulex Pharmaceuticals, Inc. (“Tulex”) as a third-party contract manufacturer to develop an oral solution for Topiramate (fka ET-101) which targets a neurological condition. The Company subsequently filed the product with the FDA in October 2020 and paid a $ 1,438 Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 12 — Commitments and Contingencies (continued) On January 23, 2019, the Company entered into a Licensing and Supply Agreement (the “Agreement”) with Liqmeds Worldwide Limited (“LMW”) for Zonisamide oral liquid, a development stage product candidate (“ET-104”). Pursuant to the terms of the Agreement, the Company was to be responsible for regulatory and marketing activities. LMW will be responsible for development and manufacturing of ET-104. The Company paid the licensor $ 350 350 325 325 650 500 10,000 35 10 On June 12, 2019, the Company entered into an Exclusive Licensing and Supply Agreement (the “ET-105 License Agreement”) with Aucta Pharmaceuticals, Inc. (“Aucta”) for marketing rights in the United States to Lamotrigine, an oral suspension product candidate for use as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients two years of age and older. Pursuant to the terms of the ET-105 License Agreement, the Company was to be responsible for marketing activities and Aucta will be responsible for development, manufacturing, and regulatory activities related to obtaining regulatory approval. The Company paid Aucta a licensing payment of $ 2,000 2,450 1,000 1,500 1,950 18,000 ● $ 1,000 when net sales exceed $10 million in a calendar year ● $ 2,000 when net sales exceed $20 million in a calendar year ● $ 5,000 when net sales exceed $50 million in a calendar year ● $ 10,000 when net sales exceed $100 million in a calendar year Eton will remain responsible for certain licensing fee obligations owed to its development partners and Azurity will assume royalty or profit share obligations owed to development partners. On March 27, 2020, the Company entered into an Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) with Diurnal Limited (“Diurnal”) for marketing Alkindi Sprinkle in the United States. Alkindi Sprinkle’s New Drug Application (NDA) was approved by the FDA on September 29, 2020 as a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. For the initial licensing milestone fee, the Company paid Diurnal $ 3,500 379,474 1,264 3.33 4,764 2,500 On June 15, 2021, the Company entered into a Distribution and Promotion License Agreement with Crossject S.A. (“Crossject”) for the U.S. and Canadian rights to Crossject’s ZENEO ® 500 upon execution of the agreement which has been included in research and development expense in the statements of operations and will pay an additional $ 500 for technical batches of the product if the technical batches are completed by December 31, 2021 and then another $ 500 for registration batches if those are completed by December 31, 2022. The Company will pay Crossject $ 1,500 upon FDA acceptance of the product filing and $ 2,000 upon FDA approval of the product. The acceptance and approval fees are subject to reduction if other hydrocortisone autoinjector intramuscular products receive FDA approval prior to the Crossject product. In addition, the Company will pay Crossject a ten percent royalty on net sales and one-time net sales milestone fees of up to $ 6,000 as indicated in the table below: Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 12 — Commitments and Contingencies (continued) ● $ 1,000 when net sales exceed $10 million in any four consecutive quarters ● $ 2,000 when net sales exceed $20 million in any four consecutive quarters ● $ 3,000 when net sales exceed $30 million in any four consecutive quarters Indemnifications As permitted under Delaware law and in accordance with the Company’s Amended and Restated Bylaws, the Company is required to indemnify its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors and officers. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of June 30, 2021 or December 31, 2020.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued)
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying interim condensed financial statements are unaudited and have been prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments necessary for the fair presentation of the Company’s financial position as of June 30, 2021 and the results of its operations and its cash flows for the periods ended June 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and six-month periods ended June 30, 2021 and 2020 are also unaudited. The results for the six-month period ended June 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods or any future year or period.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, provisions for uncollectible receivables and sales returns, valuation of inventories, useful lives of assets and the impairment of property and equipment, the accrual of research and development expenses and the valuation of common stock, stock options and warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.
Segment Information	Segment Information The Company operates the business on the basis of a single
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents are held in U.S. financial institutions or invested in short-term U.S. treasury bills. Cash equivalents consist of an interest-bearing checking account and a U.S. treasury bill. From time to time, amounts deposited with its bank exceed federally insured limits. The Company believes the associated credit risk to be minimal.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at the invoiced amount and are non-interest bearing. Accounts receivable are recorded net of allowances for doubtful accounts, cash discounts for prompt payment, distribution fees, chargebacks and returns and allowances. The total for these reserves amounted to $ 85 71
Inventories	Inventories The Company values its inventories at the lower of cost or net realizable value using the first-in, first-out method of valuation. The Company reviews its inventories for potential excess or obsolete issues on an ongoing basis and will record a write-down if an impairment is identified. Inventories at June 30, 2021 and December 31, 2020 consist solely of purchased finished goods. At both June 30, 2021 and December 31, 2020 inventories are shown net of a slow-moving reserve for its Biorphen product of $ 623 Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued)
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation of property and equipment is computed utilizing the straight-line method based on the following estimated useful lives: computer hardware and software is depreciated over three years five years estimated useful lives or the remaining lease term Maintenance and repairs are charged to expense as incurred, while renewals and improvements are capitalized. In March 2021, the Company completed an evaluation of its expected needs for product development and testing activities and determined that it would discontinue its laboratory operation in Lake Zurich, Illinois. The Company completed a sale of the lab equipment in May 2021 at a price of $ 700 which was $ 181 in excess of the book value for these assets. Accordingly, the $ 519 net book value of these assets was removed from the property and equipment accounts and the $ 181 gain is reflected in the Company’s statements of operations for the three and six-month periods ended June 30, 2021. In conjunction with the closing of its laboratory operation, the Company scrapped various furniture and equipment which had a net book value of $ 31 which has been included in research and development expense in the statements of operations.
Intangible Assets	Intangible Assets The Company capitalizes payments it makes for licensed products when the payment is based on FDA approval for the product and the cost is recoverable based on expected future cash flows from the product. The cost is amortized on a straight-line basis over the estimated useful life of the product commencing on the approval date in accordance with Accounting Standards Codification (“ASC”) 350 — Intangibles - Goodwill and Other. A $ 750 payment related to the approval of the Company’s Biorphen product in 2019 has been capitalized and that cost is being amortized over five years. The intangible assets, net on the Company’s balance sheet reflected $ 250 of accumulated amortization as of June 30, 2021. The Company recorded $ 37 75 of amortization expense for the three and six months ended June 30, 2021, respectively. The Company will record amortization expense of $ 150 per year for this intangible asset for 2021 through 2023 and then $ 125 in 2024 when it will be fully amortized.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the Company’s statements of operations for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No
Debt Issuance Costs and Debt Discount and Detachable Debt-Related Warrants	Debt Issuance Costs and Debt Discount and Detachable Debt-Related Warrants Costs incurred to issue debt are deferred and recorded as a reduction to the debt balance in the accompanying balance sheets. The Company amortizes debt issuance costs over the expected term of the related debt using the effective interest method. Debt discounts relate to the relative fair value of warrants issued in conjunction with the debt and are also recorded as a reduction to the debt balance and accreted over the expected term of the debt to interest expense using the effective interest method.
Revenue Recognition for Contracts with Customers	Revenue Recognition for Contracts with Customers The Company accounts for contracts with its customers in accordance with ASC 606 — Revenue from Contracts with Customers. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued) At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses whether these options provide a material right to the customer and, if so, they are considered performance obligations. The exercise of a material right is accounted for as a contract modification for accounting purposes. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Any amounts received prior to revenue recognition will be recorded as deferred revenue. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date will be classified as current portion of deferred revenue in the Company’s balance sheets. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as long-term deferred revenue, net of current portion. Milestone Payments Royalties – Significant Financing Component – The Company sells Biorphen in the U.S. to wholesale pharmaceutical distributors, who then sell the product to hospitals and other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement, and delivery of individual shipments of Biorphen represent performance obligations under each purchase order. The Company uses a third-party logistics (“3PL”) vendor to process and fulfill orders and has concluded it is the principal in the sales to wholesalers because it controls access to the 3PL vendor services rendered and directs the 3PL vendor activities. The Company has no significant obligations to wholesalers to generate pull-through sales. In addition, the Company sells its Alkindi Sprinkle product to one pharmacy distributor customer which provides order fulfilment and inventory storage/distribution services. Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when the wholesalers sell Biorphen at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. In addition, the Company pays fees to wholesalers for their distribution services, inventory reporting and chargeback processing. The Company pays GPOs fees for administrative services and for access to GPO members and concluded the benefits received in exchange for these fees are not distinct from its sales of Biorphen, and accordingly it applies these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past the expiration date. Because of the shelf life of Biorphen and the Company’s lengthy return period, there may be a significant period of time between when the product is shipped and when it issues credits on returned product. For its Alkindi Sprinkle product, the Company bills at the initial product list price which are subject to offsets for patient co-pay assistance and potential state Medicaid reimbursements which are recorded as a reduction of net revenues at the date of sale/shipment. Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued) The Company estimates the transaction price when it receives each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler/distributor arising from all of the above factors. The Company has developed estimates for future returns and chargebacks of Biorphen and the impact of the other discounts and fees it pays while Alkindi Sprinkle sales to its distributor are not subject to returns. When estimating these adjustments to the transaction price, the Company reduces it sufficiently to be able to assert that it is probable that there will be no significant reversal of revenue when the ultimate adjustment amounts are known. The Company recognizes revenue from Biorphen product sales and related cost of sales upon product delivery to the wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of ownership, and have an enforceable obligation to pay the Company. They also have the ability to direct sales of product to their customers on terms and at prices they negotiate. Although wholesalers have product return rights, the Company does not believe they have a significant incentive to return the product. The Company stores its Alkindi Sprinkle inventory at its pharmacy distributor customer location and sales are recorded when stock is pulled and shipped to fulfill specific patient orders. Upon recognition of revenue from product sales, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, state Medicaid and GPO fees are included in sales reserves, accrued liabilities and net of accounts receivable. The Company monitors actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts end up differing from its estimates, it will make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment. In addition, the Company receives revenues from product licensing agreements where it has contracted for milestone payments and royalties from products it has developed or for which it has acquired the rights to a product developed by a third party. Revenues for the three months ended June 30, 2021 reflected $ 2,500 of licensing milestone fees, $ 493 in product sales and $ 74 in royalty revenue. Revenues for the six months ended June 30, 2021 reflected $ 14,000 of licensing milestone fees, $ 747 in product sales and $ 217 in royalty revenue. Revenues for the three and six months ended June 30, 2020 consisted solely of product sales.
Cost of Sales	Cost of Sales Cost of sales consists of the profit-sharing and royalty fees with the Company’s product licensing and development partners, the purchase costs for finished products from third-party manufacturers and freight and handling/storage costs from the Company’s 3PL logistics service providers. The cost of sales for profit-sharing and royalty fees and costs for purchased finished products and the associated inbound freight expense is recorded when the associated product sale revenue is recognized in accordance with the terms of shipment to customers while outbound freight and handling/storage fees charged by the 3PL service provider are expensed as they are incurred. Cost of sales also reflects any write-downs or reserve adjustments for the Company’s inventories.
Research and Development Expenses	Research and Development Expenses Research and development (“R&D”) expenses include both internal R&D activities and external contracted services. Internal R&D activity expenses include salaries, benefits and stock-based compensation and other costs to support the Company’s R&D operations. External contracted services include product development efforts such as certain product licensor milestone payments, clinical trial activities, manufacturing and control-related activities and regulatory costs. R&D expenses are charged to operations as incurred. The Company reviews and accrues R&D expenses based on services performed and relies upon estimates of those costs applicable to the stage of completion of each project. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. Upfront payments and milestone payments made for the licensing of technology for products that are not yet approved by the FDA are expensed as R&D in the period in which they are incurred. Nonrefundable advance payments for goods or services to be received in the future for use in R&D activities are recorded as prepaid expenses and are expensed as the related goods are delivered or the services are performed. Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued)
Income (Loss) Per Share	Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as unvested restricted stock, stock options and warrants that are outstanding during the period. Common stock equivalents are excluded from the computation when their inclusion would be anti-dilutive. Common stock equivalents (using the treasury stock and “if converted” method) from stock options, unvested RSAs and warrants at June 30, 2021 were 1,352,879 and excluded 1,624,598 shares that were anti-dilutive (see Note 9). Included in the basic and diluted net income (loss) per share calculation are RSUs awarded to directors that have vested, but the issuance and delivery of the common shares are deferred until the director retires from service as a director (see Note 8). Basic weighted average shares for the three and six months ended June 30, 2021 include 600,000 0.01
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of ASC 718 — Compensation — Stock Compensation. The guidance under ASC 718 requires companies to estimate the fair value of the stock-based compensation awards on the date of grant and record expense over the related service periods, which are generally the vesting period of the equity awards. The Company estimates the fair value of stock-based option awards using the Black-Scholes-Merton option-pricing model (“BSM”). The BSM requires the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate was determined from the implied yields for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options or warrants. Dividends on common stock are assumed to be zero for the BSM valuation of the stock options. The expected term of stock options granted is based on vesting periods and the contractual life of the options. Expected volatilities are based on comparable companies’ historical volatility along with a limited weighting included for the Company’s own volatility subsequent to its IPO, which management believes represents the most accurate basis for estimating expected future volatility under the current conditions. The Company accounts for forfeitures as they occur.
Fair Value Measurements	Fair Value Measurements We measure certain of our assets and liabilities at fair value. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value accounting requires characterization of the inputs used to measure fair value into a three-level fair value hierarchy as follows: Level 1 Level 2 Level 3 Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below take into account the market for the Company’s financials, assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Eton Pharmaceuticals, Inc. Notes to Condensed Financial Statements ( in thousands, except share and per share amounts) (Unaudited) Note 3 — Summary of Significant Accounting Policies (continued) The Company’s financial instruments included cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, PPP loan and long-term debt obligation. The carrying amounts of these financial instruments, except for the PPP loan and long-term debt obligation, approximate their fair values due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying value of the PPP loan and long-term debt obligation approximate their fair values.
Impact of New Accounting Pronouncements	Impact of New Accounting Pronouncements There were no new accounting pronouncements issued by the FASB during the current period that would apply to the Company and have a material impact on its financial position or results of operations.
Subsequent Events	Subsequent Events The Company has evaluated subsequent events through the filing date of this Form 10-Q and has determined that no subsequent events have occurred that would require recognition in the condensed financial statements or disclosure in the notes thereto, except as disclosed in the notes to these condensed financial statements.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following: Schedule of Property and Equipment June 30, December 31, Computer hardware and software $ 153 $ 182 Furniture and fixtures 105 143 Equipment 132 994 Leasehold improvements 71 184 Property and equipment, gross 461 1,503 Less: accumulated depreciation (305 ) (692 ) Property and equipment, net $ 156 $ 811 Depreciation expense for the three-month periods ended June 30, 2021 and 2020 was $ 24 and $ 87 , respectively. Depreciation expense for the six-month periods ended June 30, 2021 and 2020 was $ 108 and $ 174 , respectively. The balances at June 30, 2021 reflect the sale of laboratory equipment in May 2021 which had a net book value of $ 519 . In conjunction with the closing of its laboratory operation, the Company scrapped various furniture and equipment which had a net book value of $ 31, which is included in research and development expense in the statements of operations.

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of Future Payments of Long Term Debt	The table below reflects the future payments for the SWK loan principal and interest as of June 30, 2021. Schedule of Future Payments of Long Term Debt Amount 2021 $ 384 2022 2,202 2023 1,756 2024 5,300 Total payments 9,642 Less: amount representing interest (2,642 ) Loan payable, gross 7,000 Less: current portion of long-term debt (749 ) Less: unamortized discount (395 ) Long-term debt, net of unamortized discount $ 5,856

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2021
Common Stock Warrants
Summary of Warrants Outstanding	The Company’s outstanding warrants to purchase shares of its common stock at June 30, 2021 are summarized in the table below. Summary of Warrants Outstanding Description of Warrants No. of Shares Exercise Price Business Advisory Warrants 600,000 $ 0.01 Placement Agent Warrants – 2017 Preferred Stock Offering 471,446 $ 3.00 Placement Agent Warrants - IPO 414,000 $ 7.50 SWK Warrants – Debt – Tranche #1 51,239 $ 5.86 SWK Warrants – Debt – Tranche #2 18,141 $ 6.62 Total 1,554,826 $ 3.18 )

Share-Based Payment Awards (Tab

Share-Based Payment Awards (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of stock option activity is as follows: Summary of Stock Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Yrs) Aggregate Intrinsic Value Options outstanding as of December 31, 2020 2,824,500 $ 4.05 8.3 $ 11,525 Issued 902,098 $ 8.61 Exercised (138,233 ) $ 2.39 Forfeited/Cancelled (12,500 ) $ 7.31 Options outstanding as of June 30, 2021 3,575,865 $ 5.25 8.4 $ 6,335 Options exercisable at June 30, 2021 1,506,614 $ 4.21 7.7 $ 3,556 Options vested and expected to vest at June 30, 2021 3,525,865 $ 5.31 8.4 $ 6,096
Schedule of Assumptions Used to Calculate Fair Value of Options Granted	The assumptions used to calculate the fair value of options granted during the six months ended June 30, 2021 under the BSM were as follows: Schedule of Assumptions Used to Calculate Fair Value of Options Granted Expected dividends — % Expected volatility 80 % Risk-free interest rate 0.9 1.1 % Expected term 5.3 6.3 Weighted average fair value $ 5.88

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Income (Loss) Per Share	Basic and diluted net income (loss) per share was calculated as follows: Schedule of Basic and Diluted Net Income (Loss) Per Share 2021 2020 2021 2020 Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Basic net income (loss) per share: Numerator: Net income (loss) $ (2,016 ) $ (4,730 ) $ 3,100 $ (13,779 ) Denominator: Weighted-average number of common shares outstanding, basic 25,211,277 21,004,910 25,132,776 19,574,164 Net income (loss) per share, basic $ (0.08 ) $ (0.23 ) $ 0.12 $ (0.70 ) Diluted net income (loss) per share: Numerator: Net income (loss) $ (2,016 ) $ (4,730 ) $ 3,100 $ (13,779 ) Denominator: Weighted-average number of common shares outstanding, basic 25,211,277 21,004,910 25,132,776 19,574,164 Dilutive effect of stock awards and warrants — — 1,352,879 — Weighted-average number of common shares outstanding, diluted 25,211,277 21,004,910 26,485,655 19,574,164 Net income (loss) per share, diluted $ (0.08 ) $ (0.23 ) $ 0.12 $ (0.70 ) Potential shares of common stock that were excluded from the computation of diluted earnings per common share as their effect was anti-dilutive: Stock awards and warrants 4,266,079 3,307,335 1,624,598 3,972,785

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases
Schedule of Lease-related Assets and Liabilities	The table below presents the lease-related assets and liabilities recorded on the balance sheet as of June 30, 2021 (in thousands). Schedule of Lease-related Assets and Liabilities Assets Classification Operating lease right-of-use assets Operating lease right-of-use assets, net $ 143 Total leased assets $ 143 Liabilities Operating lease liabilities, current Accrued liabilities $ 81 Operating lease liabilities, noncurrent Operating lease liabilities, net of current portion 58 Total operating lease liabilities $ 139
Schedule of Future Lease Commitments	The Company’s future lease commitments for its administrative offices in Deer Park, Illinois as of June 30, 2020 are as indicated below: Schedule of Future Lease Commitments Total 2021 2022 2023 Thereafter Undiscounted lease payments $ 145 43 88 14 — Less: Imputed interest (6 ) Total lease liabilities $ 139

Company Overview (Details Narra

Company Overview (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended							6 Months Ended
	Oct. 31, 2020	Aug. 31, 2020	Jun. 30, 2020	Apr. 30, 2020	Nov. 30, 2019	Nov. 30, 2018	Jun. 30, 2017	Jun. 30, 2021	Jun. 30, 2020
Subsidiary, Sale of Stock [Line Items]
Start-up capital							$ 20,055
Proceeds from loan offering		$ 1,965			$ 4,750
Proceeds from sale of shares of common stock			$ 7,756	$ 7,756					$ 7,756
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Net cash proceeds from initial public offering	$ 21,026					$ 21,960
Common stock share price per share	$ 7

Liquidity Considerations (Detai

Liquidity Considerations (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Cash Provided by (Used in) Operating Activities	$ 3,346	$ (10,070)
Cash and cash equivalents	$ 25,802		$ 21,295

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	May 31, 2021USD ($)	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2021USD ($)Segment$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)
Property, Plant and Equipment [Line Items]
Number of reportable segments | Segment				1
Accounts receivable reserves		$ 85		$ 85			$ 71
Inventory reserve		623		623			$ 623
Proceeds from Sale of Machinery and Equipment	$ 700			700
[custom:Excessbookvalueofassets-0]	$ 181
[custom:NetBookValue-0]		519		519
Gain (Loss) on Disposition of Assets		181
Payments to Acquire Intangible Assets						$ 750
[custom:ProductLicensingRightsAmortizedDescription]						cost is being amortized over five years.
Finite-Lived Intangible Assets, Accumulated Amortization		250		250
Amortization of Intangible Assets		37		75
Finite-Lived Intangible Asset, Expected Amortization, Year Three		150		150
Finite-Lived Intangible Asset, Expected Amortization, Year Four		125		125
Impairment of long-lived assets				0
Revenue from Contract with Customer, Excluding Assessed Tax		3,067	$ 20	14,964	$ 119
[custom:MilestoneFees]		$ 493		$ 747
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares		4,266,079,000	3,307,335,000	1,624,598,000	3,972,785,000
Weighted average number of shares outstanding, basic | shares		25,211,277	21,004,910	25,132,776	19,574,164
Earnings Per Share, Basic | $ / shares		$ (0.08)	$ (0.23)	$ 0.12	$ (0.70)
Vested Warrant [Member]
Property, Plant and Equipment [Line Items]
Weighted average number of shares outstanding, basic | shares		600,000		600,000
Earnings Per Share, Basic | $ / shares		$ 0.01		$ 0.01
Stock Options Awards And Warrants [Member]
Property, Plant and Equipment [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares				1,624,598
Warrant [Member]
Property, Plant and Equipment [Line Items]
Common stock equivalents. | shares				1,352,879
Licensing Revenue [Member]
Property, Plant and Equipment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 2,500		$ 14,000
Royalty [Member]
Property, Plant and Equipment [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax		74		$ 217
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives for property and equipment				3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives for property and equipment				5 years
[custom:NetBookValue-0]		$ 31		$ 31
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives for property and equipment, description				estimated useful lives or the remaining lease term

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Computer hardware and software	$ 153	$ 182
Furniture and fixtures	105	143
Equipment	132	994
Leasehold improvements	71	184
Property and equipment, gross	461	1,503
Less: accumulated depreciation	(305)	(692)
Property and equipment, net	$ 156	$ 811

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Line Items]
Depreciation	$ 24	$ 87	$ 108	$ 174
[custom:NetBookValue-0]	519		519
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
[custom:NetBookValue-0]	31		31
Imprimis Pharmaceuticals [Member]
Property, Plant and Equipment [Line Items]
[custom:NetBookValue-0]	$ 519		$ 519

Schedule of Future Payments of

Schedule of Future Payments of Long Term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
2021	$ 384
2022	2,202
2023	1,756
2024	5,300
Total payments	9,642
Less: amount representing interest	(2,642)
Loan payable, gross	7,000
Less: current portion of long-term debt	(749)
Less: unamortized discount	(395)
Long-term debt, net of unamortized discount	$ 5,856	$ 6,532

Long-Term Debt (Details Narrati

Long-Term Debt (Details Narrative) $ / shares in Units, $ in Thousands	Aug. 11, 2020USD ($)$ / shares	Jul. 21, 2020USD ($)	May 04, 2020USD ($)	Nov. 13, 2019USD ($)	Jul. 31, 2021USD ($)	Nov. 30, 2019USD ($)	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Aug. 31, 2020$ / sharesshares
Debt Instrument [Line Items]
Borrowing amount	$ 2,000			$ 2,000
Warrants issued to purchase common stock | shares							1,554,826
Warrants exercise price | $ / shares							$ 3.18
Interest expenses							$ 513	$ 386
Debt discount amortization							73	$ 50
Accrued interest							64
PPP Loan [Member]
Debt Instrument [Line Items]
Interest expenses							4
Proceeds from loan			$ 361				$ 365
EIDL Loan [Member]
Debt Instrument [Line Items]
Proceeds from loan		$ 150
EIDL Loan [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Interest expenses					$ 6
Warrant [Member]
Debt Instrument [Line Items]
Borrowing amount	2,000
Warrants issued to purchase common stock | shares							51,239		18,141
Warrants exercise price | $ / shares							$ 5.86		$ 6.62
Warrants, fair value	$ 94						$ 226
Warrants expiration term							7 years
Warrant [Member] | Measurement Input, Exercise Price [Member]
Debt Instrument [Line Items]
Warrants exercise price | $ / shares	$ 6.85						$ 5.75
Warrant [Member] | Measurement Input, Option Volatility [Member]
Debt Instrument [Line Items]
Warrant measurement input	95						95
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Warrant measurement input	0						0
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Warrant measurement input	0.4						1.8
Warrant [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Warrants expiration term	7 years
SWK Credit Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Description				On November 13, 2019, the Company entered into a credit agreement (the “SWK Credit Agreement”) with SWK Holdings Corporation (“SWK”) which provided for up to $10,000 in financing. The Company received proceeds of $5,000 at closing and was able to borrow an additional $5,000 upon the FDA approval of a second product developed by the Company, excluding EM-100. In March 2020, in conjunction with the Company’s Alkindi Sprinkle product licensing agreement (see Note 12) and the Company’s March 2020 sale of additional shares of its common stock, the Company and SWK amended the SWK Credit Agreement. The amendment provided the Company with the option to immediately draw an additional $2,000 and the ability to borrow an additional $3,000 based upon the FDA approval of EM-100 and Alkindi Sprinkle which subsequently occurred in September 2020. Accordingly, the Company borrowed an additional $2,000 on August 11, 2020. The term of the SWK Credit Agreement is for five years and borrowings bear interest at a rate of LIBOR 3-month plus 10.0%, subject to a stated LIBOR floor rate of 2.0%. A 2.0% unused credit limit fee is assessed during the first twelve months after the date of the SWK Credit Agreement and loan fees include a 5.0% exit fee based on the principal amounts drawn which is payable at the end of the term of the SWK Credit Agreement. The Company is required to maintain a minimum cash balance of $3,000, will only pay interest on the debt until February14, 2022 and then will pay 5.5% of the loan principal balance commencing on February 15, 2022 and then every three months thereafter until November 13, 2024 at which time the remaining principal balance is due. Borrowings under the SWK Credit Agreement are secured by the Company’s assets.
Borrowing amount				$ 5,000		$ 5,000
Debt Instrument, Interest Rate, Stated Percentage				5.00%
[custom:MinimumCashBalanceToBeMaintainInEachQuarterEnd]				$ 3,000
SWK Credit Agreement [Member] | Unused lines of Credit [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				2.00%
SWK Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) Swap Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				10.00%
SWK Credit Agreement [Member] | Stated LIBOR Floor Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				2.00%
SWK Credit Agreement [Member] | Food and Drug Administration's [Member]
Debt Instrument [Line Items]
Borrowing amount				$ 5,000
SWK Credit Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Borrowing amount				$ 10,000

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2021	Apr. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized	50,000,000		50,000,000		50,000,000		50,000,000
Common stock, par value	$ 0.001		$ 0.001		$ 0.001		$ 0.001
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of stock issued for exercise of stock warrants					135,650
Intrinsic value of the warrants exercised					$ 806
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			63,233	64,878	138,233	69,878
Stock Issued During Period, Shares, New Issues				100,000		2,600,000
Number of stock issued for exercise of stock warrants					94,808
Employee stock purchase plan, shares			29,326	14,005	29,326	14,005
Employees [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Employee stock purchase plan, shares	29,326
Restricted Stock Units (RSUs) [Member] | Board of Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock Issued During Period, Shares, New Issues		25,000
2018 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					138,233

Summary of Warrants Outstanding

Summary of Warrants Outstanding (Details)	Jun. 30, 2021$ / sharesshares
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
No. of Shares, Total | shares	1,554,826
Exercise Price | $ / shares	$ 3.18
Business Advisory Warrants [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
No. of Shares, Total | shares	600,000
Exercise Price | $ / shares	$ 0.01
Placement Agent Warrants - 2017 Preferred Stock Offering [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
No. of Shares, Total | shares	471,446
Exercise Price | $ / shares	$ 3
Placement Agent Warrants - IPO [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
No. of Shares, Total | shares	414,000
Exercise Price | $ / shares	$ 7.50
SWK Warrants - Debt Tranche #1 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
No. of Shares, Total | shares	51,239
Exercise Price | $ / shares	$ 5.86
SWK Warrants - Debt Tranche #2 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
No. of Shares, Total | shares	18,141
Exercise Price | $ / shares	$ 6.62

Summary of Stock Option Activit

Summary of Stock Option Activity (Details) - Equity Option [Member] $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Summary of Investment Holdings [Line Items]
Shares, Options Outstanding, Beginning Balance | shares	2,824,500
Weighted Average Exercise Price, Options Outstanding, Beginning Balance | $ / shares	$ 4.05
Weighted Average Remaining Contractual Term, Options Outstanding, Beginning Balance	8 years 3 months 18 days
Aggregate Intrinsic Value, Options Outstanding, Beginning Balance | $	$ 11,525
Shares, Issued | shares	902,098
Weighted Average Exercise Price, Issued | $ / shares	$ 8.61
Shares, Exercised | shares	(138,233)
Weighted Average Exercise Price, Exercised | $ / shares	$ 2.39
Shares, Forfeited/Cancelled | shares	(12,500)
Weighted Average Exercise Price, Forfeited/Cancelled | $ / shares	$ 7.31
Shares, Options Outstanding, Ending Balance | shares	3,575,865
Weighted Average Exercise Price, Options Outstanding, Ending Balance | $ / shares	$ 5.25
Weighted Average Remaining Contractual Term, Options Outstanding, Ending Balance	8 years 4 months 24 days
Aggregate Intrinsic Value, Options Outstanding, Ending Balance | $	$ 6,335
Shares, Options Exercisable, Ending Balance | shares	1,506,614
Weighted Average Exercise Price, Options Exercisable, Ending Balance | $ / shares	$ 4.21
Weighted Average Remaining Contractual Term, Options Exercisable, Ending Balance	7 years 8 months 12 days
Aggregate Intrinsic Value, Options Exercisable, Ending Balance | $	$ 3,556
Shares, Options Vested and Expected to Vest, Ending Balance | shares	3,525,865
Weighted Average Exercise Price, Options Vested and Expected to Vest, Ending Balance | $ / shares	$ 5.31
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	8 years 4 months 24 days
Aggregate Intrinsic Value, Options Vested and Expected to Vest, Ending Balance | $	$ 6,096

Schedule of Assumptions Used to

Schedule of Assumptions Used to Calculate Fair Value of Options Granted (Details) - $ / shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	0.00%	0.00%
Expected volatility	80.00%
Share Price	$ 5.88
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.90%
Expected term	5 years 3 months 18 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.10%
Expected term	6 years 3 months 18 days

Share-Based Payment Awards (Det

Share-Based Payment Awards (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2018	Apr. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Sep. 30, 2017	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2018	May 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 836	$ 714		$ 1,509	$ 1,079
Expected dividend yield						0.00%	0.00%
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			691	651		$ 1,272	$ 976
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense			$ 145	$ 63		$ 237	$ 103
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			63,233	64,878		138,233	69,878
Employee stock purchase plan, shares			29,326	14,005		29,326	14,005
Four Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period						138,233	69,878
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price						$ 2.39	$ 1.39
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value						$ 661	$ 139
Product Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options issued to purchase common stock						50,000
Product Consultant [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options expiration period						5 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as compensation					100,000
Restricted Stock [Member] | Outside Directors One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as compensation					25,000
Restricted Stock [Member] | Outside Directors Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as compensation					25,000
Restricted Stock [Member] | Outside Directors Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as compensation					25,000
Restricted Stock [Member] | Outside Directors Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as compensation					25,000
Shares issued as vested compensation		25,000
Restricted Stock [Member] | Four Outside Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares to outside directors vesting percentage	100.00%
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options expiration period							10 years
Non-Vested Stock Option Awards and Restricted Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount			$ 8,242			$ 8,242
2017 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									5,000,000
2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement, shares available for future issuance			481,160			481,160
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period						138,233
2018 Equity Incentive Plan [Member] | January 1, 2019 and Through January 1, 2028
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage for total number of shares outstanding						4.00%
2018 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement, shares available for future issuance			500,009			500,009		150,000
Stock-based compensation expense						$ 46	$ 33
Share based compensation for initial shares reserve, description						The Company’s ESPP provides for an initial reserve of 150,000 shares and this reserve is automatically increased on January 1 of each year by the lesser of 1% of the outstanding common shares at December 31 of the preceding year or 150,000 shares, subject to reduction at the discretion of the Company’s board of directors
Description for deductions to purchase stock at price per share						The terms of the ESPP permit employees of the Company to use payroll deductions to purchase stock at a price per share that is at least the lesser of (1) 85% of the fair market value of a share of common stock on the first date of an offering or (2) 85% of the fair market value of a share of common stock on the date of purchase. After the initial offering period ended, subsequent twelve-month offering periods automatically commence over the term of the ESPP on the day that immediately follows the conclusion of the preceding offering, each consisting of two purchase periods approximately six months in duration.
Employee stock purchase plan, shares						29,326	14,005
Weighted average grant date fair value issued						$ 2.83	$ 2.43
Employees contribution amount						$ 135	$ 66
Accrued liabilities for remaining employee contributions			$ 19	$ 9		$ 19	$ 9

Schedule of Basic and Diluted N

Schedule of Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Net income (loss)	$ (2,016)	$ (4,730)	$ 3,100	$ (13,779)
Weighted-average number of common shares outstanding, basic	25,211,277	21,004,910	25,132,776	19,574,164
Net income (loss) per share, basic	$ (0.08)	$ (0.23)	$ 0.12	$ (0.70)
Dilutive effect of stock awards and warrants			1,352,879,000
Weighted-average number of common shares outstanding, diluted	25,211,277	21,004,910	26,485,655	19,574,164
Net income (loss) per share, diluted	$ (0.08)	$ (0.23)	$ 0.12	$ (0.70)
Stock awards and warrants	4,266,079,000	3,307,335,000	1,624,598,000	3,972,785,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

Feb. 18, 2019

Jan. 23, 2019

Nov. 17, 2017

Aug. 11, 2017

May 31, 2021

Apr. 30, 2021

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2018

Dec. 31, 2020

Related Party Transaction [Line Items]

Common stock issued

24,600,175

24,600,175

24,312,808

Common stock par value per share

$ 0.001

$ 0.001

$ 0.001

Proceeds from Sale of Machinery and Equipment

$ 700,000

$ 700,000

Payment of research and development expense

$ 1,990,000

$ 1,609,000

$ 2,876,000

$ 7,877,000

Credit agreement term

10 years

10 years

Imprimis Pharmaceuticals [Member]

Related Party Transaction [Line Items]

Proceeds from Sale of Machinery and Equipment

700

[custom:GainOnSaleOfLabEquipment]

$ 181

Eyemax [Member] | Amended and Restated Agreement [Member]

Related Party Transaction [Line Items]

Sale of product expense

$ 2,000,000

Eyemax [Member] | Amended and Restated Agreement [Member] | One Milestone [Member]

Related Party Transaction [Line Items]

Related party transaction

250,000

Eyemax [Member] | Amended and Restated Agreement [Member] | Two Milestone [Member]

Related Party Transaction [Line Items]

Related party transaction

$ 500,000

Harrow Health Inc. [Member]

Related Party Transaction [Line Items]

Common stock issued

3,500,000

3,500,000

Common stock par value per share

$ 0.001

$ 0.001

Harrow Health Inc. [Member] | Common Stock [Member]

Related Party Transaction [Line Items]

Restricted stock award forfeited

20,000

Harrow Health Inc. [Member] | Restricted Stock [Member]

Related Party Transaction [Line Items]

Number of restricted common stock issued for services

1,500,000

Number of stock options issued to purchase common stock

130,000

Harrow Health Inc. [Member] | Restricted Stock [Member] | Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Number of restricted common stock issued for services

25,000

Eyemax [Member]

Related Party Transaction [Line Items]

Related party transaction

$ 250,000

Payment of research and development expense

250,000

Sale of product expense

$ 500,000

Percentage of royalty fee

10.00%

Related party transaction, description

The Eyemax Agreement was for an initial term of 10 years from the date of the Eyemax Agreement, subject to successive two-year renewals unless the Company elected to terminate the Eyemax Agreement.

Credit agreement term

10 years

Schedule of Lease-related Asset

Schedule of Lease-related Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Customer Securities for which Entity has Right to Sell or Repledge (Including Securities Sold or Repledged) [Line Items]
Total leased assets	$ 143	$ 192
Operating lease liabilities, current	139
Operating Lease Right-of-use Assets [Member]
Customer Securities for which Entity has Right to Sell or Repledge (Including Securities Sold or Repledged) [Line Items]
Total leased assets	143
Accrued Liabilities [Member]
Customer Securities for which Entity has Right to Sell or Repledge (Including Securities Sold or Repledged) [Line Items]
Operating lease liabilities, current	81
Operating Lease Liabilities [Member]
Customer Securities for which Entity has Right to Sell or Repledge (Including Securities Sold or Repledged) [Line Items]
Operating lease liabilities, current	$ 58

Schedule of Future Lease Commit

Schedule of Future Lease Commitments (Details) - Operating Lease Liability [Member] $ in Thousands	Jun. 30, 2021USD ($)
Customer Securities for which Entity has Right to Sell or Repledge (Including Securities Sold or Repledged) [Line Items]
Undiscounted lease payments	$ 145
2021	43
2022	88
2023	14
Thereafter
Less: Imputed interest	(6)
Total lease liabilities	$ 139

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Cash paid for operating lease liabilities			$ 43
ROU asset amortization	$ 20	$ 33	$ 49	$ 64
Weighted-average remaining lease term	1 year 9 months		1 year 9 months
Weighted-average incremental borrowing rate	5.40%		5.40%
Research and Development Expense [Member]
Operating lease cost	$ 0	14	$ 9	28
General and Administrative Expense [Member]
Operating lease cost	$ 22	$ 20	$ 43	$ 41

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

Aug. 16, 2021

Jun. 15, 2021

Mar. 26, 2020

Jun. 12, 2019

Feb. 08, 2019

Jan. 23, 2019

Nov. 17, 2017

Oct. 31, 2020

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Product Liability Contingency [Line Items]

Percentage of net profits payments to third party from sale of product

50.00%

Litigation related product profit, percentage

6250.00%

Credit agreement term

10 years

10 years

Payments for development

$ 1,990

$ 1,609

$ 2,876

$ 7,877

Value of common stock shares issued

$ 297

7,756

Tulex Pharmaceuticals [Member]

Product Liability Contingency [Line Items]

Payment of filing fee

$ 1,438

Diurnal Limited [Member]

Product Liability Contingency [Line Items]

Payment for obtaining product orphan drug

$ 2,500

Exclusive License and Supply Agreement (ET-202 ) [Member]

Product Liability Contingency [Line Items]

Payment of milestone fee

$ 600

Exclusive License and Supply Agreement (ET-202 ) [Member] | Licensor [Member]

Product Liability Contingency [Line Items]

Credit agreement term

10 years

Exclusive License and Supply Agreement (ET-202 ) [Member] | Upon FDA Approval [Member]

Product Liability Contingency [Line Items]

Payment of licensing

$ 750

Exclusive License and Supply Agreement (ET-202 ) [Member] | Sintetica [Member]

Product Liability Contingency [Line Items]

Payment of licensing

$ 2,000

Percentage of net sales as marketing fees

5.00%

Proceeds from licensing

$ 500

Percentage for additional profit

50.00%

Exclusive License and Supply Agreement (ET-203) [Member]

Product Liability Contingency [Line Items]

Percentage for additional profit

50.00%

Exclusive License and Supply Agreement (ET-203) [Member] | Sintetica [Member]

Product Liability Contingency [Line Items]

Payment of licensing

$ 1,000

Percentage of net sales as marketing fees

5.00%

Proceeds from licensing

$ 500

Percentage for additional profit

50.00%

License and Supply Agreement (ET-203) [Member] | Licensor [Member]

Product Liability Contingency [Line Items]

Credit agreement term

10 years

Licensing and Supply Agreement [Member] | Licensor [Member]

Product Liability Contingency [Line Items]

Percentage of net profits payments to third party from sale of product

35.00%

Payments for development

$ 350

Licensing and Supply Agreement [Member] | Upon FDA Approval [Member] | Licensor [Member]

Product Liability Contingency [Line Items]

Payments for development

325

Licensing and Supply Agreement [Member] | Upon Successful Bioequivalence Study [Member] | Licensor [Member]

Product Liability Contingency [Line Items]

Payments for development

350

Licensing and Supply Agreement [Member] | Upon FDA Acceptance [Member] | Licensor [Member]

Product Liability Contingency [Line Items]

Payments for development

325

Licensing and Supply Agreement [Member] | Upon Issuance of Patent Covering [Member] | Licensor [Member]

Product Liability Contingency [Line Items]

Payments for development

650

Licensing and Supply Agreement [Member] | Product Sales [Member] | Licensor [Member]

Product Liability Contingency [Line Items]

Payments for development

500

Licensing and Supply Agreement [Member] | Calendar Year [Member] | Licensor [Member]

Product Liability Contingency [Line Items]

Payments for development

$ 10,000

Exclusive License and Supply Agreement (ET-105 ) [Member] | Aucta Pharmaceuticals, Inc [Member]

Product Liability Contingency [Line Items]

Payment of licensing

$ 2,000

Exclusive License and Supply Agreement (ET-105 ) [Member] | Aucta Pharmaceuticals, Inc [Member] | Maximum [Member]

Product Liability Contingency [Line Items]

Milestone payment amount

18,000

Exclusive License and Supply Agreement (ET-105 ) [Member] | Upon FDA Approval [Member] | Aucta Pharmaceuticals, Inc [Member]

Product Liability Contingency [Line Items]

Payment of licensing

2,450

Exclusive License and Supply Agreement (ET-105 ) [Member] | Upon Issuance of Orange-book Listed Patent [Member] | Aucta Pharmaceuticals, Inc [Member]

Product Liability Contingency [Line Items]

Payment of licensing

1,000

Exclusive License and Supply Agreement (ET-105 ) [Member] | Upon FDA Acceptance of Product Filing [Member] | Aucta Pharmaceuticals, Inc [Member]

Product Liability Contingency [Line Items]

Payment of licensing

1,500

Exclusive License and Supply Agreement (ET-105 ) [Member] | Upon FDA Approval and Commercial Sales [Member] | Aucta Pharmaceuticals, Inc [Member]

Product Liability Contingency [Line Items]

Payment of licensing

$ 1,950

Exclusive License and Supply Agreement (ET-105 ) [Member] | Sales Exceed $10 Million [Member] | Aucta Pharmaceuticals, Inc [Member]

Product Liability Contingency [Line Items]

Milestone payment description

1,000 when net sales exceed $10 million in a calendar year

Exclusive License and Supply Agreement (ET-105 ) [Member] | Sales Exceed $20 Million [Member] | Aucta Pharmaceuticals, Inc [Member]

Product Liability Contingency [Line Items]

Milestone payment description

2,000 when net sales exceed $20 million in a calendar year

Exclusive License and Supply Agreement (ET-105 ) [Member] | Sales Exceed $50 Million [Member] | Aucta Pharmaceuticals, Inc [Member]

Product Liability Contingency [Line Items]

Milestone payment description

5,000 when net sales exceed $50 million in a calendar year

Exclusive License and Supply Agreement (ET-105 ) [Member] | Sales Exceed $100 Million [Member] | Aucta Pharmaceuticals, Inc [Member]

Product Liability Contingency [Line Items]

Milestone payment description

10,000 when net sales exceed $100 million in a calendar year

Exclusive License and Supply Agreement [Member] | Diurnal Limited [Member]

Product Liability Contingency [Line Items]

Cash paid for licensing milestone fee

$ 3,500

Number of common stock shares issued

379,474

Value of common stock shares issued

$ 1,264

Shares issued price per share

$ 3.33

Aggregate value of licensing milestone amount included in research and development expense

$ 4,764

Distribution and Promotion License Agreement [Member] | Crossject S.A. [Member]

Product Liability Contingency [Line Items]

Payments for development

$ 500

$ 500

Royalty percentage

1000.00%

Distribution and Promotion License Agreement [Member] | Crossject S.A. [Member] | Maximum [Member]

Product Liability Contingency [Line Items]

Cash paid for licensing milestone fee

$ 6,000

Distribution and Promotion License Agreement [Member] | Upon FDA Acceptance of Product Filing [Member] | Crossject S.A. [Member]

Product Liability Contingency [Line Items]

Payments for development

1,500

Distribution and Promotion License Agreement [Member] | Upon FDA Approval and Commercial Sales [Member] | Crossject S.A. [Member]

Product Liability Contingency [Line Items]

Payments for development

$ 2,000

Distribution and Promotion License Agreement [Member] | Sales Exceed $10 Million [Member] | Crossject S.A. [Member]

Product Liability Contingency [Line Items]

Milestone payment description

1,000 when net sales exceed $10 million in any four consecutive quarters

Distribution and Promotion License Agreement [Member] | Sales Exceed $20 Million [Member] | Crossject S.A. [Member]

Product Liability Contingency [Line Items]

Milestone payment description

2,000 when net sales exceed $20 million in any four consecutive quarters

Distribution and Promotion License Agreement [Member] | Sales Exceed $30 Million [Member] | Crossject S.A. [Member]

Product Liability Contingency [Line Items]

Milestone payment description

3,000 when net sales exceed $30 million in any four consecutive quarters